ImmunityBio
IBRX
59 hedge funds and large institutions have $219M invested in ImmunityBio in 2015 Q3 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64% less call options, than puts
Call options by funds: $510K | Put options by funds: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
+$98.1M |
| 2 |
CC
Callan Capital
La Jolla,
California
|
+$79.3M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$58.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$42M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.4M |
Top Sellers
IBRX Hedge Fund Activity: Q3 2015 in Review
59 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2015, worth a combined $219M.
Buyers outnumbered sellers: 59 funds opened new IBRX positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wildcat Capital Management, opening a new position worth an estimated $98.1M.
- 59 institutional investors held ImmunityBio (IBRX) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $219M of ImmunityBio stock for Q3 2015.
- 59 funds opened new ImmunityBio positions in Q3 2015 and 0 closed out, a net change of +59 holders.
- The largest ImmunityBio buyer in Q3 2015 was Wildcat Capital Management, an estimated $98.1M added.
Based on aggregated 13F filings for Q3 2015.